Table 2. Results of the analyses of predictors of the presence of microvascular invasion in patients with hepatocellular cancer undergoing liver transplantation.
| Factors | Univariable | Multivariable | ||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Recipient male gender | 1.02 (0.72–1.43) | 0.932 | ||
| Recipient age | 1.03 (0.99–1.07) | 0.192 | ||
| MELD | 0.94 (0.88–1.01) | 0.088 | ||
| HCV infection | 0.84 (0.61–1.17) | 0.306 | ||
| HBV infection | 0.72 (0.52–1.01) | 0.054 | ||
| Alcoholic liver disease | 1.31 (0.89–1.92) | 0.177 | ||
| Number of tumors | 1.28 (1.12–1.46) | <.001 | 1.34 (1.13–1.59) | 0.001 |
| Size of the largest tumor | 1.31 (1.09–1.56) | 0.004 | 1.33 (1.07–1.64) | 0.009 |
| Total tumor volume | 1.08 (1.02–1.15) | 0.005 | ||
| Pre-transplant AFP | 1.20 (1.04–1.38) | 0.013 | 1.18 (1.01–1.39) | 0.049 |
| Poor tumor differentiation | 1.55 (1.01–2.39) | 0.050 | ||
| Neoadjuvant treatment | 1.16 (0.63–2.15) | 0.638 | ||
Odds ratios were given per: 1 year increase for recipient age; 1 point increase for model for end-stage liver disease; 1 tumor more for number of tumors; 1 cm increase for the size of the largest tumor; 10 cm3 increase for total tumor volume; 1 loge increase for alpha-fetoprotein. OR – odds ratio; 95% CI – 95% confidence interval; MELD – model for end-stage liver disease; HCV – hepatitis C virus; HBV – hepatitis B virus; AFP – alpha-fetoprotein.